title: Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis.
authors.affiliation: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. marina.kremyanskaya@mssm.edu.
authors.forename: Marina
authors.initials: M
authors.lastname: Kremyanskaya
authors.forename: John
authors.initials: J
authors.lastname: Mascarenhas
authors.forename: Raajit
authors.initials: R
authors.lastname: Rampal
authors.forename: Ronald
authors.initials: R
authors.lastname: Hoffman
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000209:etiology*; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011720:Pyrazoles / Q000009:adverse effects*; D011743:Pyrimidines; D023981:Sarcoma, Myeloid / Q000175:diagnosis / Q000209:etiology*
chemical_list: D000970:Antineoplastic Agents; D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D053612:Janus Kinases
keywords: acute myeloid leukaemia; clinical haematology; haematological malignancies; myelofibrosis